ClinicalTrials.gg
RecruitingNCT05939180Updated Sep 2, 2026

VA vs DA for Newly Diagnosed Hig-risk AML

A Phase 2/3 interventional study of Venetoclax Oral Tablet and Daunorubicin in Acute Myeloid Leukemia, sponsored by The First Affiliated Hospital of Soochow University. Recruiting at 2 sites in China. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-09-02.

Sponsored by The First Affiliated Hospital of Soochow University · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Phase
Phase 2/3
Study type
Interventional
Enrollment
116
Allocation
Randomized
Ages
18 Years to 64 Years
Sex
All
01

Study summary

This is an open-label, multicenter, phase 2b, randomized study aiming to compare the efficacy and safety of venetoclax plus azacytidine Versus daunorubicin plus cytarabine (conventional 7+3 regimen) in adult acute myeloid leukemia (AML) patients with adverse risk featuress. Participants will be 1:1 randomly assigned to the VA and DA groups. Once remission was achieved, consolidated chemotherapy will be performed and allogeneic hematopoietic stem cell transplantation is strongly recommended. After completion of the study intervention, participants will be followed-up every 1 to 2 months for up to 2 years.

Read the detailed description

This is an open-label, multicenter, phase 2b, randomized study aiming to compare the efficacy and safety of venetoclax plus azacytidine Versus daunorubicin plus cytarabine (conventional 7+3 regimen) in adult acute myeloid leukemia (AML) patients with adverse risk featuress. Newly diagnosed AML patients with adverse risk features according to 2022 European Leukemia Net risk stratification will be enrolled. In the study, a novel second generation targeted sequencing panel for the fast screening of adverse mutations with 72-hours after the bone marrow samples will be utilized. Randomized participants will receive induction treatment . Participants will be 1:1 randomly assigned to the VA and DA groups. VA regimen comprises of azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28. DA regimen comprises of daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle. Once remission was achieved, consolidated chemotherapy will be performed and allogeneic hematopoietic stem cell transplantation is strongly recommended. After completion of the study intervention, participants will be followed-up every 1 to 2 months for up to 2 years.

02

Conditions studied

  • Acute Myeloid Leukemia

Keywords

  • Adverse risk, newly diagnosed, induction therapy
03

In context

Leukemia, Myeloid, Acute

3,667 studies on the registry are indexed under Leukemia, Myeloid, Acute; 816 are open to participants now.

This study's planned enrollment of 116 is above the median of 40 across 3,005 interventional studies indexed under Leukemia, Myeloid, Acute.

Browse Leukemia, Myeloid, Acute studies →

Lead sponsor

The First Affiliated Hospital of Soochow University is the lead sponsor of 261 studies on the registry; 150 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 64 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Gender: female or male.
  2. Age:18-64 years old.
  3. Patients with newly diagnosed AML according to the WHO 2022 classification.
  4. AML patients with adverse risk features according to the 2022 European Leukemia Net risk stratification.
  5. Untreated AML (hydroxyurea, and low dose cytarabine with cummulative dose \<1.0g are permitted).
  6. : 0-2.
  7. Adequate liver function: Total ≤ 1.5× (ULN); (AST) ≤3×ULN (liver infiltration of leukemia: ≤5×ULN); alanine aminotransferase (ALT)≤3×ULN (liver infiltration of leukemia: ≤5×ULN) .
  8. Adequate Renal function: Ccr ( Rate) ≥30 ml/min.
  9. Be able to understand and be willing to participate in the study. Be able to provide written .

Exclusion criteria

Exclusion Criteria:

  1. Patients with acute promyeloid leukemia.
  2. AML with central nervous system infiltration.
  3. Patients diagnosed with myeloid sarcoma.
  4. Patients have AML secondary to MDS and previously been treated with hypomethylating agents.
  5. Patients with active infection, which is considered as uncontrollable by the investigator.
  6. Patients with active , and infection.
  7. Patients with heart failure (grade 3-4);
  8. Patients who are pregnant or breastfeeding.
  9. Patients who refused to be enrolled in the study. Patients who are considered as ineligible for the enrollment by the investigators.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
116 participants (estimated)

Study arms

  • Experimental
    VA regimen

    VA regimen: azacytidine and venetoclax

    Drug: Venetoclax Oral Tablet

  • Active comparator
    DA regimen

    DA regimen: daunorubicin and cytarabine

    Drug: Daunorubicin

Interventions

  • VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.

    Also known as: venetoclax plus azacytidine

  • DA regimen: daunorubicin (60mg/m2) on days 1-3, intraveneously injection, and cytarabine (100mg/m2) on days 1-7, intraveneously injection, for 1 cycle.

    Also known as: daunorubicin plus cytarabine

06

What researchers measure

Primary outcomes

  1. Composite complete remission (CRc) after one course of induction therapy

    Rates of complete remission plus complete remission with incomplete blood cell rates of complete remission or complete remission with incomplete marrow recovery

    Time frame: From randomization to the end of the first course of induction therapy (within 28 days)

Secondary outcomes

  1. DOR: duration of remission

    Time between the first remission and relapse

    Time frame: 2 years

  2. EFS:event-free survival

    time from the date of enrollment to treatment failure, relapse, death from any cause or the last follow-up

    Time frame: 2 years

  3. OS: overall survival

    time from the date of enrollment to death from any cause or the last follow-up

    Time frame: 2 years

  4. Volume of infused blood products

    The volume of infused blood products during the induction treatment.

    Time frame: Within 60 days after randomization

  5. AE

    Adverse events during the induction treatment.

    Time frame: Within 60 days after randomization

  6. Composite complete remission (CRc) after two courses of induction therapy

    complete remission or complete remission with incomplete marrow recovery

    Time frame: From randomization to the end one and two courses of induction therapy (within 60 days)

07

Study locations

2 of 2 sites recruiting
  • The First Affiliated Hospital of Soochow University, Jiangsu Institute of Hematology
    Suzhou, Jiangsu 215000, China
    Recruiting
  • Ethical Committee of the First Affliated Hospital of Soochow University
    Suzhou, Jiangsu 215006, China
    Recruiting
    • Zhou-lin Lu · Contact13914086271
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Sep 2, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05939180
Responsible party
Sponsor
First posted
Jul 11, 2023
Start date
Apr 1, 2024
Primary completion
Jun 13, 2026
Completion
May 13, 2028 (estimated)
Last update
Sep 2, 2026

Study contacts

Su-ning Chen
Contact
chensuning@sina.com
008613814881746
Su-ning Chen
principal investigator · The First Affiliated Hospital of Soochow University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Venetoclax

Start the discussion